The Biology of Eosinophils and Their Role in Asthma

Claire N. McBrien1* and Andrew Menzies-Gow2

1 Imperial College London, London, United Kingdom, 2 Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom

This review will describe the structure and function of the eosinophil. The roles of several relevant cell surface molecules and receptors will be discussed. We will also explore the systemic and local processes triggering eosinophil differentiation, maturation, and migration to the lungs in asthma, as well as the cytokine-mediated pathways that result in eosinophil activation and degranulation, i.e., the release of multiple pro-inflammatory substances from eosinophil-specific granules, including cationic proteins, cytokines, chemokines growth factors, and enzymes. We will discuss the current understanding of the roles that eosinophils play in key asthma processes such as airway hyperresponsiveness, mucus hypersecretion, and airway remodeling, in addition to the evidence relating to eosinophil–pathogen interactions within the lungs.

Keywords: eosinophils, asthma, IL-5, eosinophil receptors, respiratory tract infections, asthma exacerbation

INTRODUCTION

The three main processes responsible for the clinical features of asthma are well recognized: bronchoconstriction, mucus hypersecretion, and airway inflammation. However, the underlying pathophysiology responsible for these processes is complex and nuanced, involving multiple cell types and cytokines (1). Furthermore, the activity and clinical impact of each cellular and subcellular component varies considerably between individuals and can change over time, as well as in response to drug therapy and environmental/lifestyle influences.

Among these myriad cellular interactions and this extremely heterogeneous patient group, it is possible to identify certain key cells that are commonly involved—of which, arguably, the eosinophil is the most important.

Eosinophil precursors originate in the bone marrow and following differentiation traffic to the lungs (among other sites) via the bloodstream (2). While high concentrations of circulating eosinophils are often measured in asthmatic patients, of more clinical relevance is the lung tissue eosinophilia that is also frequently present.

The phenotype of "severe eosinophilic asthma" refers to a subgroup of asthmatic patients with evidence of eosinophilia that often require high maintenance doses of oral corticosteroids to maintain reasonable disease control. The notoriously non-specific mechanisms of action of corticosteroid therapy give rise to numerous well-documented adverse effects (3), which have driven decades of research focused on the development of targeted anti-eosinophil drug therapies. In order to understand how to better assist this group of patients, who currently have an unmet clinical need, it is helpful to understand the eosinophil itself, and the role that it plays in asthma. Targeted anti-eosinophil therapies will be touched upon but will be covered in greater detail by other reviews in this Research Topic.
EOSINOPHIL CELL STRUCTURE

Eosinophils are granulocytes, typically measuring 10–16 µm in diameter. They possess segmented (usually bi-lobed) nuclei and their nucleus: cytoplasm ratio is approximately 30%. Eosinophils stain with acidophilic dyes—a feature noted in 1879 by Paul Ehrlich, who first described eosinophils and appreciated their increased presence in patients with asthma and helminth infections, among other conditions (4). See Figure 1 for an overview of the eosinophil ultrastructure.

The presence of large specific granules, also known as secondary granules, is a characteristic feature that distinguishes eosinophils from other granulocytes (neutrophils and basophils). Specific granules consist of a dense crystalline core and a matrix, surrounded by a membrane (5). They contain a large number of mediators capable of inducing inflammation and/or tissue damage, including basic proteins, cytokines, chemokines, growth factors, and enzymes. The predominant substances are the proteins: major basic protein (MBP) is located in the core, while the matrix contains eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN) (6).

Primary granules tend to be smaller than specific granules. They are the principal location of Charcot–Leyden crystal protein (galactin-10): hexagonal bipyramidal crystals, which exhibit lysophospholipase activity and have been identified in tissues subject to eosinophilic inflammation (7).

Lipid bodies are particularly important when considering the role of eosinophils in asthma, due to their involvement in the production of eicosanoids, including cysteinal leukotrienes, prosta glandins, and thromboxane (2). Lipid bodies are a key site of arachidonic acid esterification and eicosanoid production due to their high concentrations of relevant enzymes such as cyclooxygenases, 5-lipoxygenase, and leukotriene C4-synthase (3).

Golgi bodies, endoplasmic reticulum, and mitochondria are also present and fulfill the fundamental duties of protein and adenosine triphosphate production within the eosinophil.

The histological appearance of eosinophils varies depending on the level of activation. For example, higher numbers of vesicles such as eosinophil sombrero vesicles may be seen when the cell is undergoing piecemeal degranulation (PMD), a process described in detail further on.

EOSINOPHIL SURFACE MOLECULES AND RECEPTORS

The varied roles of the eosinophil are reflected in its wide repertoire of surface molecules and receptors, which integrate eosinophils with both the innate and adaptive immune systems.
Cytokine and Growth Factor Receptors
The heterodimeric receptor for IL-5 is thought to be the most important cytokine receptor expressed by eosinophils. The beta-subunit is identical to the beta-subunit of the receptors for granulocyte–macrophage colony-stimulating factor (GM-CSF) and IL-3 (both of which are also present on eosinophil cell membranes). The alpha-subunit, IL-5Rα, is specific to IL-5 and has been identified as a therapeutic target for severe eosinophilic asthma and other eosinophil-mediated conditions. The IL-5 receptor is also expressed by basophils.

Eosinophils also express receptors for multiple other cytokines and growth factors, including for IL-4, IL-13, IL-33, thymic stromal lymphopoietin, and transforming growth factor-β (TGF-β).

Chemoattractant Receptors
Chemokines are small cytokines, which stimulate the migration of specific subsets of leukocytes. Chemokines are divided into four groups, depending on the presence or absence of one or more interposing amino acid(s) between two cysteine residues (known as CXC-, CCX-, and CC-chemokines), or the presence of only one cysteine residue (XC-chemokines) (8).

CC-chemokine receptor-3 (CCR3) is an important G protein-coupled receptor expressed on eosinophil cell membranes. CCR3 binds to all three subtypes of eotaxin (a variety of CC-chemokine that functions as a selective eosinophil chemoattractant). CCR3 also binds to several other chemokines including monocyte chemoattractant protein-3 (MCP-3) and MCP-4. The airways of patients with asthma have been shown to contain higher numbers of cells expressing mRNA for CCR3 and its ligands, compared to non-asthmatic control subjects (9). In mouse models of allergic airway inflammation, antigen-induced airway eosinophilia may be inhibited by the administration of either a monoclonal antibody against CCR3 (10) or a low molecular weight CCR3-antagonist (11).

CCR1 is another key chemokine receptor on eosinophils, which is activated by chemoattractant cytokine ligand-3 (CCL-3) and CCL-5 (also known as RANTES—regulated on activation, normal T cell expressed and secreted).

Lipid Mediator Receptors
Eosinophils possess cell surface receptors for lipid mediators such as leukotrienes, prostaglandins, and platelet-activating factor, all of which have been shown to have a role in asthma pathophysiology (12–14). Eosinophils also express several other families of PRR, including retinoic acid-inducible gene-I-like receptors, nucleotide-binding oligomerisation domain-like (NOD-like) receptors, and the receptor for advanced glycation endproducts (RAGE) (15).

Fc Receptors
Fc receptors to IgA, IgD, IgE, IgG, and IgM are expressed on the surface of eosinophils, facilitating interaction with the adaptive immune system.

The high-affinity FcεRI receptor binds IgE and signals via intracellular tyrosine kinases. On mast cells and basophils, where FcεRI is expressed as a tetramer (αβγ2), stimulation by IgE results in degranulation. However, on eosinophils, FcεRI is usually expressed in very small quantities as a trimer (without a β chain) and has no role in eosinophil activation (17). In contrast, cross-linking of FcαRI and FcγRII, with IgA and IgG, respectively, has been shown to trigger eosinophil activation (18).

Major Histocompatibility Complex-II (MHC-II)
Eosinophils have an additional role as antigen-presenting cells, facilitated by the presence of MHC-II molecules and co-stimulatory molecules such as CD80 and CD86. In allergic patients, evaluated after segmental antigen challenge, expression of HLA-DR (a subtype of MHC-II molecule) was found to be approximately four times greater in lung eosinophils compared to blood eosinophils (19).

Adhesion Receptors
Adhesion receptors, as their name suggests, allow cells such as the eosinophil to adhere to the extracellular matrix (ECM) and to other cells. They also allow the eosinophil to sense its surroundings and respond accordingly. Adhesion receptors are divided into four main groups: integrins, cadherins, selectins, and immunoglobulin-like cell adhesion molecules (Ig-CAM). Integrins and selectins are the main forms of adhesion receptors expressed on eosinophil cell membranes.

Eosinophils express seven types of integrins, which are transmembrane glycoproteins, consisting of an α and a β chain (20). Examples include very late antigen-4 (VLA-4, CD49d/CD29) and the complement receptor CR3 (CD11b/CD18), which is otherwise known as macrophage-1 antigen (Mac-1).

Selectins are single-chain transmembrane glycoproteins with multiple domains. There are three families: E-, L-, and P-selectin; the latter two are expressed by human eosinophils, whereas E-selectin is present on activated endothelium (21).

Siglec-8
Siglec-8 is a sialic acid immunoglobulin-like lectin (a carbohydrate-binding protein) expressed by eosinophils, mast cells, and basophils. Its physiological role has not yet been identified, although it is thought to represent a potential therapeutic target for eosinophil-mediated disease, due to the observation that administration of an antibody targeted against Siglec-8 can induce selective eosinophil apoptosis and inhibit mast cell degranulation (22).
EOSINOPHIL DIFFERENTIATION, MATURATION, MIGRATION, ACTIVATION, AND DEGRANULATION

Eosinophils develop from pluripotent CD34+ granulocyte progenitor cells.

Differentiation and maturation occur as follows:

Myeloblast → Promyelocyte → Eosinophil myelocyte → Eosinophil metamyelocyte → Eosinophil.

Allergen challenge of mild asthmatics results in increased expression of IL-5Rα on CD34+ cells in the bone marrow, associated with blood and sputum eosinophilia (23). Eosinophil differentiation usually occurs in the bone marrow. However, eosinophil precursors have been isolated from the peripheral blood of atopic subjects at significantly higher concentrations compared to non-atopic controls (24). Increased numbers of CD34+/IL-5Rα+ eosinophil precursors have also been identified in bronchial biopsies of atopic asthmatics, compared to non-atopic control subjects (both atopic and non-atopic) (25). Eosinophil-lineage committed cells have also been identified in lung tissue in a mouse model of allergic airway inflammation (26). More recently, eosinophil progenitors isolated from the blood of patients with severe eosinophilic asthma have been shown to have an exaggerated clonogenic response to IL-5 in vitro, compared to eosinophil precursors from mild asthmatics, suggesting that in situ eosinophilopoièsis may have a clinically relevant role in severe eosinophilic asthma (27).

The differentiation of eosinophils is regulated by the transcription factors GATA-binding protein 1 (GATA-1), PU.1, and the CCAAT-enhancing binding protein (c/EBP) family. GATA-1 and PU.1 synergistically promote transcription of MBP (28). GATA-1 is thought to have the most important role, as disruption of the GATA-1 gene in mice results in a strain completely devoid of eosinophil progenitor cells.

The cytokines IL-3, IL-5, and GM-CSF also synergistically contribute to the development of mature eosinophils (30). IL-5 is the most eosinophil-specific and also promotes the release of eosinophils from the bone marrow to the bloodstream, acting synergistically with eotaxin (31, 32). Eosinophils are present in relatively low numbers in peripheral blood, usually accounting for no more than 5% of the total white blood cell count (33). They have a relatively short blood half-life of approximately 18 h (34). Migration to specific body sites, including the lungs and intestines, is mediated by eosinophil chemoattractants such as eotaxins. Eotaxins are a variety of CC-chemokines. There are three known subtypes: eotaxin-1 (CCL-11), eotaxin-2 (CCL-24), and eotaxin-3 (CCL-26). These bind to CCR3 receptors on the cell membranes of eosinophils and induce chemotaxis. 5-oxo 6, 8, 11, 14-eicosatetraenoic acid (5-oxo-ETE) is another eosinophil chemoattractant.

In vitro, the presence of prostaglandin-D2 (PGD2) has been shown to significantly enhance the chemoattractant effects of eotaxin-1 and 5-oxo-ETE on eosinophils and—unlike eotaxin-1 or 5-oxo-ETE—PGD2 retains its chemoattractant effect in the presence of blood or plasma (35). It is therefore proposed that PGD2 acts as the initial chemoattractant, triggering the migration of circulating eosinophils to specific tissues, where eotaxins and 5-oxo-ETE then predominate. PGD2 is released from activated mast cells (36) and acts via CRTh2 (chemoattractant receptor-homologous molecule expressed on T H2 cells).

In allergic inflammation and asthma, circulating eosinophils adhere to the vascular endothelium and roll along it, before extravasating to the lung tissue. Initial tethering to the endothelium occurs as a result of the eosinophil cell membrane adhesion receptor P-selectin binding to P-selectin glycoprotein ligand-1 on the endothelium (37). Binding of the integrin VLA-4 to vascular cell adhesion molecule-1 promotes eosinophil activation and extravasation (37). IL-13 results in increased eosinophil expression of P-selectin and increased P-selectin mediated adhesion to endothelial cells (38).

The eosinophil’s ability to store several preformed cytotoxic mediators ready for rapid release upon appropriate stimulation facilitates a much quicker reaction to pro-inflammatory stimuli, compared to other cells, whose responses depend on upregulating the transcription of genes coding for such proteins.

The bronchial epithelium produces the cytokines IL-25, IL-33, and thymic stromal lymphopoietin, collectively known as the alarmins, in response to irritants such as allergens, pollutants, and pathogens. These cytokines trigger an inflammatory cascade involving, among others, T helper-2 (Th2) cells and type-2 innate lymphoid cells (ILCs2), resulting in increased production of numerous cytokines including IL-4, IL-5, and IL-13, therefore prompting eosinophil activation (1, 39).

High mobility group box 1 protein, acting via receptors TLR-2, TLR-4, and RAGE, also promotes eosinophilia, although less is known regarding its mechanism of action (2).

Specific granule contents may be released via three different degranulation processes. Conventional exocytosis entails the specific granules fusing with the eosinophil cell membrane, resulting in the release of the entire contents of the specific granule. Alternatively, the eosinophil may be lysed (cytolysis), releasing all the cell contents, including the intact specific granules. These extracellular granules can be found in tissues affected by eosinophil-mediated disease and may subsequently release their contents in response to pro-inflammatory stimuli (40). However, the most common mechanism of eosinophil granulation is termed piecemeal degranulation (PMD). In this process, vesicles (both round and tubular) are released from specific granules and travel to the cell membrane to discharge their contents to the extracellular domain (41). The tubular vesicles tend to curl into a hoop-like morphology, giving rise to the term “eosinophil sombrero vesicles” (42). Vesicles with particular contents may be selectively released in response to particular cytokines, allowing eosinophils to supply a specific combination of cytotoxic mediators on demand (42, 43).

The activation of TLRs on eosinophils has been shown to promote adhesion and the release of certain cytokines and superoxides (44). Activation of TLR-2 and TLR-9 triggers eosinophil degranulation (44, 45). In vitro, eosinophils from atopic subjects have been shown to produce more IL-8 and EDN in response to stimulation of TLR-7 and TLR-9, compared to healthy controls (45).
Eosinophil survival is promoted by IL-3, IL-5, GM-CSF, and eotaxin (37). Activation of TLR-7 (the most abundant TLR subtype expressed by eosinophils) also enhances eosinophil survival (45).

**IL-3, IL-5, AND GM-CSF**

Among the type-2 cytokines, IL-3, IL-5, and GM-CSF are particularly important for the initiation and perpetuation of eosinophilic airway inflammation. These three cytokines are closely linked, in that the genes for all three are all located on chromosome 5, and their receptors also share a common β-subunit (βc).

Monoclonal antibodies against IL-5 have been developed in order to treat eosinophil-mediated diseases such as eosinophilic asthma. Although inhibition of IL-5 activity in this manner (using mepolizumab) results in significant depletion of circulating eosinophils, the effect on bronchial tissue eosinophilia is less marked, with a median reduction of 55% (46). The residual tissue eosinophilia may reflect ongoing effects mediated by IL-3 and GM-CSF. In a mouse model of allergic airways inflammation, allergen-induced lung tissue eosinophilia was abolished in mice bred to lack the common β-subunit, therefore incapable of responding to IL-3, IL-5, and GM-CSF (47). In the same study, lung tissue from βc-deficient mice was found to contain fewer myeloid dendritic cells, and the local T<sub>H2</sub>2 cells showed a reduced ability to proliferate and produce type-2 cytokines (47). These findings suggest a multifactorial role for the common β-subunit in the regulation of allergic airway inflammation.

**THE ROLE OF THE EOSINOPHIL IN HEALTH**

In comparison to the roles that eosinophils play in diseases and infections, relatively little is known about their purpose in health. However, an increasing number of homeostatic mechanisms have been attributed to—or at least associated with—eosinophils in recent years. This has prompted a call for a fundamental change of the perception of eosinophils purely as cytotoxic effector cells (48, 49).

In health, eosinophils are found in the thymus, spleen, lymph nodes, and gastrointestinal (GI) tract (50). The number of eosinophils in the thymus declines with age (51). Eosinophils may have a role in T cell selection. In a mouse model of MHC I-restricted acute negative selection, eosinophil recruitment to the corticomedullary region of the thymus and association with apoptotic bodies has been demonstrated (52). Eosinophils also enhance the ability of macrophages to phagocytose apoptotic thymic cells (53).

Eosinophils migrate to the GI tract during embryonic development, i.e., prior to the development of any viable gut flora (54). In health, they are present throughout the GI tract—with the notable exception of the esophagus. Eosinophils contribute to the immune defense against gut microorganisms, due to multiple antimicrobial properties. (The antimicrobial properties of eosinophils are discussed in detail further on, with specific relation to respiratory pathogens.) Other potential homeostatic roles for eosinophils within the gut are not currently well defined but may relate to their ability to interact with the enteric neuronal system and increase smooth muscle reactivity (via release of MBP) (55).

In murine white adipose tissue, a positive correlation was identified between eosinophil counts and the numbers of arginase-1-expressing macrophages (56). Macrophages expressing arginase-1 are thought to contribute to glucose homeostasis, although macrophage classification is contentious (57). In a more recent study involving more than 9,000 human participants, the peripheral blood eosinophil percentage was found to be inversely associated with the risk of type-2 diabetes mellitus and insulin resistance (58).

Eosinophils have also been implicated in the regeneration of liver tissue (59) and skeletal muscle (60). The increased presence of eosinophils in preovulatory ovarian follicles (61) and in endometrium (62) has prompted speculation that they may have a role in tissue remodeling related to ovulation and menstruation. Eosinophils also perform several important immunomodulatory functions, discussed in the following section.

**THE EOSINOPHIL’S ROLE IN ASTHMA PATHOPHYSIOLOGY**

Asthma pathophysiology is complex, and the relative contributions of the various cytokine networks involved vary between patients. Core features include airway hyperresponsiveness (AHR), mucus hypersecretion, tissue damage, and airway remodeling. See Figure 2 for an overview of the eosinophil’s role in asthma pathophysiology.

It has long been observed that eosinophil counts in peripheral blood and bronchoalveolar lavage (BAL) fluid are higher in asthmatics compared to healthy controls (63). Analysis of BAL fluid obtained from patients with atopic asthma reveals increased expression of T<sub>H2</sub>2 cytokines (64), including IL-5, which are strongly associated with eosinophilic inflammation (65). In general, the degree of eosinophilia correlates with disease severity and exacerbation frequency (63, 66). However, non-eosinophilic asthma phenotypes are also recognized (67). Peripheral blood eosinophilia may also occur in numerous other conditions (see Box 1).

**AHR and Mucus Hypersecretion**

Eosinophils may be prompted to release a number of different mediators with the capacity to cause AHR. Human MBP is known to result in AHR when administered to primates (70) and rats (71). In the former study, administration of EPO also caused AHR, although ECP and EDN did not (70). Data from the latter study suggested the mechanism of action involved the stimulation of bradykinin production (71). MBP can also trigger mast cells and basophils to release histamine, a potent mediator of bronchial hyperreactivity (72, 73).

Eosinophils are a source of several cytokines including IL-13, which causes AHR, and also promotes mucus hypersecretion via enhanced differentiation of goblet cells (74). IL-13 is also
**FIGURE 2** | The role of eosinophils in asthma. An overview of the main stimuli for eosinophilic airway inflammation (gray boxes) and the means by which eosinophils elicit the main pathophysiological changes associated with asthma (green boxes). Abbreviations: MBP, major basic protein; EPO, eosinophil peroxidase; IL, interleukin; TGF-β, transforming growth factor-β; GM-CSF, granulocyte-macrophage colony-stimulating factor; PGD2, prostaglandin-D2; 5-oxo-ETE, 5-oxo 6, 8, 11, 14-eicosatetraenoic acid; PAMPs, pathogen associated molecular patterns; DAMPs, damage associated molecular patterns; Ig, immunoglobulin.

**BOX 1** Alternative (i.e., non-asthma) causes of peripheral eosinophilia (68, 69).

Respiratory
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Allergic bronchopulmonary aspergillosis
- Sarcoidosis

Hematological and neoplastic
- Myeloproliferative hypereosinophilic syndrome
- Lymphocytic-variant hypereosinophilic syndrome
- Certain leukemias and lymphomas
- Systemic mastocytosis
- Solid tumors—adenocarcinomas, squamous cell carcinomas, large cell lung carcinomas, transitional cell carcinoma of the bladder

Infective
- Parasitic infection, in particular helminths
- Human immunodeficiency virus

Dermatological
- Eczema
- Scabies infestation

Iatrogenic
- Certain drug hypersensitivity reactions
- Graft vs host disease

produced by T_h2 cells and ILC2s. Lipid mediators such as leukotrienes, which are produced in eosinophil lipid bodies (and mast cells), also cause AHR and mucus hypersecretion (75).

Studies involving two different strains of eosinophil-deficient mice have attempted to clarify the role of eosinophils in an ovalbumin model of asthma but yielded seemingly contradictory results. In one study, performed by Lee et al., eosinophil-deficient mice were protected from AHR and mucus hypersecretion (76). However, another study, led by Humbles, found that eosinophil deficiency was not protective in this regard (77). Several theories have been put forward to explain the conflicting results, including evidence of residual lung eosinophils in the Humbles study and differences between the underlying mouse strains (78).

In terms of practical application, the existence in humans of eosinophilic bronchitis, a condition characterized by marked airway eosinophilia in the absence of AHR, calls into question the concept that eosinophils—acting alone—have a clinically significant impact on AHR. In patients with mild asthma, administration of a monoclonal antibody to IL-5 has been shown to reduce blood and sputum eosinophilia but had no effect on AHR (79). This may reflect the cellular redundancy of AHR pathophysiology, which involves several cell types including T_h2 cells, ILC2s,
and mast cells. In addition, the current evidence relating to AHR does not specifically study the pathophysiology of asthma exacerbations, during which it is possible that eosinophil degranulation may contribute to worsening AHR.

**Tissue Damage and Airway Remodeling**

Postulation that eosinophils are major effectors of lung tissue damage in asthma is well founded, given their propensity to release highly charged basic proteins, which exert multiple cytotoxic effects. MBP is toxic to respiratory epithelial cells *in vitro* and has been identified in postmortem lung tissue specimens of patients who have died of asthma, in association with epithelial damage (80). ECP and EDN share 67% amino acid sequence homology and tend to be grouped together as eosinophil-associated RNases, although ECP’s RNase activity is much less potent (81). ECP binds to cell membranes and alters their permeability (82). EDN, as its name suggests, is neutotoxic. It was first identified following the observation that, in rabbits, the intracerebral administration of eosinophils resulted in the destruction of cerebellar Purkinje cells and neurological features named “the Gordon phenomenon” (83, 84). EPO catalyzes the oxidation of halides and thiocyanate, resulting in cytotoxic reactive oxidant species (85).

Cell damage triggers the activation of repair pathways which, if excessive, may contribute to structural changes referred to as airway remodeling. The underlying pathological processes include hyperplasia of fibroblasts, airway smooth muscle (ASM) and goblet cells, deposition of ECM proteins, and angiogenesis (86). Airway remodeling is associated with the severity of asthma (87). It has been hypothesized that airway remodeling is responsible for the accelerated decline in lung function and development of fixed airway obstruction observed in some asthmatic patients. However, bronchial biopsies of children with difficult asthma have been shown to display reticular basement membrane thickening to a similar degree compared with adult asthmatics (88). Furthermore, there is evidence that some pathological features of airway remodeling can become evident within 24 h of allergen exposure (89).

Eosinophils release multiple growth factors and fibrogenic mediators that promote airway remodeling (see Table 1). For example, eosinophils are known to produce TGF-β1 in disease states involving the skin (atopy) (90), nose (nasal polyposis) (91), and blood (idiopathic hypereosinophilic syndrome) (92). Eosinophils are the main source of TGF-β in bronchial biopsies taken from asthmatic patients (93) and can also stimulate epithelial cells to produce a number of mediators, including TGF-β (94). TGF-β is implicated in tissue remodeling *via* fibroblast proliferation and increased production of collagen and glycosaminoglycans (95–97).

Eosinophils isolated from asthmatics, when cocultured with ASM cells, promote enhanced ASM proliferation, which is inhibited by the addition of the leukotriene antagonist montelukast (117). It appears that eosinophils and ASM enjoy a reciprocal relationship, as ASM cells are also known to produce eosinophil cytokines (118). Mouse studies lend further support to the assertion that eosinophils have an important role in airway remodeling, as eosinophil-deficient mice are protected against airway deposition of collagen and smooth muscle (77).

**Asthma Exacerbations**

Airway eosinophilia is an early feature of asthma exacerbations. In a study of steroid-dependent asthmatic patients, whose prednisolone dose was gradually reduced to below their maintenance requirement, the sputum eosinophil count started to rise 4 weeks before the blood eosinophil count and 6 weeks prior to spirometric and symptomatic deterioration (120). In fact, the adoption of an asthma treatment strategy based on sputum eosinophilia rather than traditional markers of disease activity (such as symptoms and spirometry) was found to reduce the frequency of exacerbations, with no overall increase in the average daily corticosteroid dose (121).

The primary action of anti-IL-5 therapies appears to be a reduction in exacerbation frequency. Administration of mepolizumab to selected patient groups reduced exacerbation rates by approximately 50% (122–124). A similar reduction in exacerbation rates was seen with reslizumab, another anti-IL-5 monoclonal antibody (125). Mepolizumab has also been found to have a moderate glucocorticoid-sparing effect in a phase III clinical trial (126).

Benralizumab is a monoclonal antibody targeted against the alpha subunit of the IL-5 receptor (IL-5Rα). As well as blocking the interaction between IL-5 and its receptor, benralizumab causes eosinophil cell death *via* antibody-dependent cell-mediated cytotoxicity (127), resulting in striking (95%) airway eosinophil depletion (128). Phase III clinical trials have demonstrated reductions in exacerbation rates (129, 130).

**Immunomodulation**

In addition to the direct effects of eosinophils on asthma pathophysiology, they have an important role in immunomodulation (2). MBF, released from eosinophil-specific granules, stimulates inflammatory responses from neutrophils (increased production of superoxide and IL-8) (131) and mast cells (increased histamine release) (72). Nerve growth factor (also released from specific granules) has also been shown to prolong the survival of neutrophils (132) and mast cells (133). EDN promotes the activation of dendritic cells (134), which in turn trigger the proliferation of T cells (both helper and cytotoxic) and B cells *via* antigen presentation. Eosinophils themselves can also present antigens to T cells (135, 136).

The cytokines released from eosinophil-specific granules have various immunomodulatory effects. For example, IL-4 and IL-13 simulate the proliferation of B cells and IgE production (137, 138), and IL-6 enhances survival of plasma cells (139, 140). Eosinophil-specific granules are also capable of releasing several chemokines. Depending on the stimulation they receive, these include CCL-17 and CCL-22, which attract T<sub>H</sub>2 cells, and CXCL-9 and CXCL-10, which are T<sub>H</sub>1 chemokines (141). In addition, eosinophils express indoleamine 2,3-dioxygenase (IDO), an enzyme that catalyzes the production of kynurenine,
TABLE 1 | Factors produced by eosinophils that are associated with airway remodeling.

| Factor                  | Mechanism(s) and evidence                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TGF-β                   | • Epithelial/submucosal expression of TGF-β correlates with basement membrane thickness and fibroblast numbers (98).  
|                         |  
|                         | • In allergen-challenged human atopic skin, eosinophils expressing TGF-β1 are associated with myofibroblast formation and deposition of tenascin and procollagen-1 (99).  
|                         |  
|                         | • TGF-β induces hypertrophy and increased contractility of ASM in vitro (100).  
|                         |  
|                         | • Administration of anti-TGF-β antibody to mice with established eosinophilic airway inflammation significantly reduces airway remodelling (101).  
| MMP-9 and TIMP-1         | • MMP-9 breaks down ECM proteins; TIMP-1 inhibits MMP-9.  
|                         |  
|                         | • Sputum MMP-9 and TIMP-1 concentrations are higher in asthmatics compared to controls; The MMP-9/TIMP-1 ratio is lower in patients with asthma and chronic bronchitis, and positively correlates with FEV1 (102).  
|                         |  
|                         | • MMP-9 is required for angiogenesis in mice (103).  
| VEGF, bFGF, and angiogenin | • VEGF, bFGF, and angiogenin promote angiogenesis.  
|                         |  
|                         | • Bronchial biopsies of asthmatics exhibit greater immunoreactivity to VEGF, bFGF, and angiogenin; Immunoreactivity to these factors positively correlates with vascular area (104).  
| Specific granule proteins | • MBP and ECP are toxic to airway epithelial cells.  
|                         |  
|                         | • Damaged airway epithelium produces TGF-β (105).  
|                         |  
|                         | • ECP induces fibroblast migration (106) and inhibits fibroblast-mediated proteoglycan degradation (107).  
| IL-17                   | • Fibroblasts isolated from bronchial biopsies produce more IL-6 and IL-11 (proliferotic cytokines) when stimulated by IL-17 (108).  
|                         |  
|                         | • In a mouse model of asthma, administration of IL-17A results in increased vascular remodelling; in vitro, IL-17A accelerates EPC migration (109).  
| IL-13                   | • Mice bred to overexpress IL-13 exhibit eosinophilic airway inflammation, epithelial cell hypertrophy, mucus metaplasia, and subepithelial fibrosis (109).  
|                         |  
|                         | • In vitro, IL-13 induces human bronchial epithelial cells to release TGF-β (110).  
| HB-EGF                  | • Recombinant HB-EGF promotes migration of ASM cells in vitro and accelerates the thickening of the ASM layer in a mouse model of asthma (111).  
| NGF                     | • NGF causes migration of vascular smooth muscle cells and fibroblasts, and proliferation of epithelial cells and ASM cells (112).  
|                         |  
|                         | • In mice with chronic allergen-induced airway inflammation, anti-NGF antibodies reduce airway collagen deposition (113).  
| Cysteinyl leukotrienes  | • In a mouse model of allergen-induced airway remodelling, administration of montelukast (a CysLT1 receptor blocker) reverses established ASM layer thickening and subepithelial fibrosis (114).  
| SCF                     | • SCF promotes mast cell proliferation and activation.  
|                         |  
|                         | • Mast cells produce TNF-α, which can damage bronchial epithelial cells (115) and stimulate fibroblasts to produce TGF-β (116).  

**Notes:** TGF, transforming growth factor; MMP, matrix metalloproteinase; ECM, extracellular matrix; TIMP, tissue inhibitor of metalloproteinase; FEV1, forced expiratory volume in 1 s; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; MBP, major basic protein; ECP, eosinophil cationic protein; IL, interleukin; EPC, endothelial progenitor cell; HB-EGF, heparin-binding epidermal growth factor-like growth factor; ASM, airway smooth muscle; TNF, tumor necrosis factor.

suppressing Th1 activity and promoting a type-2 inflammatory milieu (142, 143).

See Figure 3 for an overview of the eosinophil’s immunomodulatory roles in asthma.

**INTERACTIONS BETWEEN EOSINOPHILS AND RESPIRATORY PATHOGENS**

Eosinophils have traditionally been regarded as end-stage effector cells, responding to infections directly, i.e., by releasing substances that are toxic to pathogens (in particular, helminths) and resulting in the unwanted secondary effect of human tissue damage. However, research performed over the last 30 years has revealed additional roles fulfilled by the eosinophil, involving links with both the innate and adaptive immune systems. These roles include antigen presentation and interaction with other parts of the immune system, such as the complement pathway (144).

Pattern recognition receptors on the cell membranes of eosinophils allow them to detect the presence of PAMPs such as lipopolysaccharide (LPS) and beta-glucans, cell wall components of bacteria and fungi, respectively (144). The cytotoxic and serine proteases produced by mites and fungi activate eosinophils via protease-activated receptors (5). TLR-7, the most common TLR expressed by eosinophils, is activated by viral single-stranded RNA (2).

The contents of eosinophil-specific granules are directly cytotoxic to pathogens. MBP causes disruption of cell membranes due to its highly basic nature (145). ECP has antiviral activity (146) and can also agglutinate Gram-negative bacteria by binding to LPS and peptidoglycans (147). EDN is only mildly toxic to helminths, compared to MBP and ECP (148). However, EDN significantly reduces the infectivity of respiratory syncytial virus group B, indicating a role in the immune response to viruses (149). EPO facilitates the generation of toxic reactive oxygen species (150).

In addition to releasing cytotoxic proteins, eosinophils have been shown to phagocytose bacteria (albeit less efficiently than neutrophils) (151). More recently, the “catapult-like” extrusion of “traps” consisting of mitochondrial DNA and eosinophil granule contents, in response to Gram-negative bacteria, has been observed (152).
Eosinophils express receptors for various complement proteins, including C3a and C5a, which are known to promote eosinophil recruitment, extravasation, and activation (153, 154). Complement is thought to facilitate eosinophil adherence to, and damage of, nematode larvae (155), although the development of secondary immunity is unaffected in complement-deficient mice (156).

As fungi are known to trigger the production of TH2-associated cytokines (i.e., type-2 cytokines) and eosinophilia, it has been hypothesized that subclinical fungal infection/colonization of the airways may play a role in the genesis of diseases characterized by eosinophilia. Such diseases include severe eosinophilic asthma, as well as related conditions (e.g., chronic rhinosinusitis). One study of patients undergoing sinus surgery found that 74% of those with TH2-associated conditions had evidence of airway surface mycosis, compared to just 16% of controls (157). However, potential confounding factors such as inhaled and/or systemic corticosteroid usage must be considered.

The increased susceptibility to respiratory viral infections observed in patients with asthma has been linked to reduced production of type I and type III interferons (158, 159). Eosinophils may contribute to this impairment by producing TGF-β, which has been shown to diminish the ability of bronchial epithelial cells to produce interferons in response to human rhinovirus in vitro (160).

The lung is known to harbor communities of bacteria, known as the lung microbiome, during health, which are deranged in disease states including asthma (161, 162). Data have recently been published suggesting a possible link between the level of eosinophilia and microbiome community structure in asthma (163). Further dedicated studies, examining subject groups matched for baseline characteristics, are required.

**CONCLUSION**

Although eosinophils have been associated with asthma since their initial discovery, our understanding of their roles in health and disease has evolved significantly over time. The eosinophil’s status as a cytotoxic effector cell appears to be justified, due its capacity to release potent destructive basic proteins, capable of antimicrobial effects as well as host tissue damage. However, its ability to modulate the innate and adaptive immune systems may be just as important.

An appreciation of the numerous receptors expressed by eosinophils offers some insight into the many different interactions this versatile cell is capable of. Not only is the eosinophil recruited to the lungs in the context of pro-inflammatory type-2 cytokines but it is also a promoter of the type-2 inflammatory milieu, taking on roles such as antigen presentation and cytokine-mediated modulation of local lymphocytes.
There is strong evidence that eosinophils contribute to airway remodeling in asthma. Mechanisms also exist by which eosinophils could promote AHR and mucus hypersecretion. The development of new anti-eosinophilic drugs, capable of selective depletion of eosinophils, offers great potential to explore further questions relating to the role of eosinophils in asthma and the consequences of their eradication. Research into variation in eosinophil-related gene expression between individuals may provide further insights regarding the relative contributions of eosinophils in different asthma phenotypes and the potential application of personalized medicine to this field.

REFERENCES

1. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol (2015) 16(1):45–56. doi:10.1038/ni.3049
2. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol (2013) 13(1):9–22. doi:10.1038/nri3341
3. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med (2006) 100(8):1307–17. doi:10.1016/j.rmed.2005.11.020
4. Gleich GJ. Chapter 1 – Historical overview and perspective on the role of the eosinophil in health and disease A2 – Lee, James J. In: Rosenberg HF, editor. Eosinophils in Health and Disease. Boston: Academic Press (2013). p. 1–11.
5. Shamri R, Xenakis JJ, Spencer LA. Eosinophils in innate immunity: an evolving story. Cell Tissue Res (2011) 343(1):57–83. doi:10.1007/s00441-010-1049-6
6. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev (1999) 51(2):233–340.
7. Dvorak AM, Letourneau L, Login GR, Weller PF, Ackerman SJ. Ultrastructural localization of the Charcot-Leyden crystal protein (lysocephospholipase) to a distinct crystalloid-free granule population in mature human eosinophils. Blood (1988) 72(1):150–8.
8. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol (2000) 18:217–42. doi:10.1146/annurev.immunol.18.1.217
9. Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfarlane A, Humbert M, et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemotractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (atopic) asthmatics. J Immunol (1999) 163(1):6321–9.
10. Justice JP, Borchers MT, Crosby JR, Hines EM, Shen HH, Ochkrur SI, et al. Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. Am J Physiol Lung Cell Mol Physiol (2003) 284(1):L169–78. doi:10.1152/ajplung.00260.2002
11. Komai M, Tanaka H, Nagao K, Ishizaki M, Kajiwara D, Miura T, et al. A novel CC-chemokine receptor 3 antagonist, Kit9003, inhibits airway eosinophilia and subepithelial/peribronchial fibrosis induced by repeated antigen challenge in mice. J Pharmacol Sci (2010) 112(2):203–13. doi:10.1254/jphs.09277FP
12. Singh RK, Tandon R, Dastidar SG, Ray A. A review on leukotrienes and their receptors with reference to asthma. J Asthma (2013) 50(9):922–31. doi:10.3109/02786123.2013.823447
13. Bisgaard H. Leukotrienes and prostaglandins in asthma. Allergy (1984) 39(6):43–20. doi:10.1111/1398-9995.1984.tb01963.x
14. Palgan K, Bartuzzi Z. Platelet activating factor in allergies. Int J Immunopharmacol Pharmacol (2015) 28(4):584–9. doi:10.17265/0943-3210.201500598
15. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell (2010) 140(6):805–20. doi:10.1016/j.cell.2010.01.022
16. Dembic Z. The Function of Toll-Like Receptors, in Madame Curie Bioscience Database [Internet]. Austin, TX: Landes Bioscience (2000–2013).
17. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol (2010) 125(2 Suppl 2):573–80. doi:10.1016/j.jaci.2009.11.017
18. Muraki M, Gleich GJ, Kita H. Antigen-specific IgG and IgA, but not IgE, activate the effector functions of eosinophils in the presence of antigen. Int Arch Allergy Immunol (2011) 154(2):119–27. doi:10.1159/000320226

AUTHOR CONTRIBUTIONS

CM performed the initial literature review and drafted the article. AM-G provided critical review and additional content.

FUNDING

CM is a clinical research fellow, whose post is funded by the Asmarley Charitable Trust via Imperial College London. AM-G is a consultant respiratory physician, employed by the Royal Brompton and Harefield NHS Foundation Trust.
53. Kim HJ, Alonzo ES, Dorothee G, Pollard JW, Sant’Angelo DB. Selective deple-
tion of eosinophils or neutrophils in mice impacts the efficiency of apoptotic
cell clearance in the thymus. PLoS One (2010) 5(7):e11439. doi:10.1371/
journal.pone.0011439

54. Mishra A, Hogan SR, Lee JJ, Foster PS, Rothenberg ME. Fundamental signals
that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest
(1999) 103(12):1719–27. doi:10.1172/JCI16560

55. Jacoby DB, Gleich GJ, Fryer AD. Human eosinophil major basic protein is an
endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor.
J Clin Invest (1993) 94(1):1314–8. doi:10.1172/JCI16331

56. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouhaan HA, Bando JK, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science (2011) 332(6026):243–7. doi:10.1126/science.1210475

57. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerd S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 41(1):14–20. doi:10.1016/j.immuni.
2014.06.008

58. Zhu L, Su T, Xu M, Xu Y, Li M, Wang T, et al. Eosinophil inversely associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS One (2013) 8(7):e67613. doi:10.1371/journal.pone.0067613

59. Goh YP, Henderson NC, Heredia JE, Red Eagle A, Odegaard JJ, Lehwald N, et al. Eosinophils secrete IL-4 to facilitate liver regeneration. Proc Natl Acad Sci U S A (2013) 110(24):9914–9. doi:10.1073/pnas.130406110

60. Heredia JE, Mukundan L, Chen FM, Mueller AA, Des RC, Locksley RM, et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell (2013) 153(2):376–88. doi:10.1016/j.cell.2013.02.053

61. Aust G, Simchen C, Heider U, Hmeidan FA, Blumenauer V, Spanel-Borowski K. Eosinophils in the human corpus luteum: the role of RANTES and eotaxin in eosinophil attraction into periovulatory structures. Mol Reprod Dev (2000) 57(7):205–14. doi:10.1002/(SICI)1098-2472(20000601)57:7<205::AID-MRD9>3.0.CO;2-1

62. Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Endothelin and possible mechanisms. Semin Hematol. (2002) 39(4):300–304. doi:10.1053/shem.2002.019089

63. Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med (2000) 343(15):1033–9. doi:10.1056/NEJM200010043130515

64. Robinson DS, Hamid Q, Ying S, Tiscupoulos A, Barkans J, Bentley AM, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med (2002) 347(25):1987–94. doi:10.1056/
NEJM200206273472501

65. Sur S, Gleich GJ, Swanson MC, Bartermes KR, Broide DH. Eosinophilic inflammation is associated with elevation of interleukin-5 in the airways of patients with spontaneous symptomatic asthma. J Allergy Clin Immunol (1995) 95(5 Pt 1):661–8. doi:10.1016/S0021-9624(95)70139-2

66. Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med (2015) 3(11):849–58. doi:10.1016/s2213-
2600(15)00367-7

67. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: impos-
tance and possible mechanisms. Thorax (2002) 57(7):643–8. doi:10.1136/
 thorax.57.7.643

68. Meija R, Nutman TB. Evaluation and differential diagnosis of marked, non-IgE-
mediated eosinophilic inflammation and possible mechanisms. J Allergy Clin Immunol (2010) 126(1):45–59. doi:10.1016/j.jaci.2010.03.042

69. Gleich GJ, Swanson MC, Bartermes KR, Broide DH. Eosinophilic inflammation in asthma. N Engl J Med (2000) 343(15):1033–9. doi:10.1056/NEJM200010043130515

70. Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Endothelin and possible mechanisms. Semin Hematol. (2002) 39(4):300–304. doi:10.1053/shem.2002.019089

71. Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med (2000) 343(15):1033–9. doi:10.1056/NEJM200010043130515

72. Piliponsky AM, Gleich GJ, Nagler A, Bar I, Levi-Schaffer F. Non-IgE-
dependent activation of human lung- and cord blood-derived mast cells is
induced by eosinophil major basic protein and modulated by the membrane
form of stem cell factor. Blood (2003) 101(5):1898–904. doi:10.1182/blood-
2002-05-1488
73. Ben-Zamra M, Bachelet I, Seaf M, Gleich GJ. Eosinophil major basic protein activates human cord blood mast cells primed with fibroblast membrane factors by integrin-beta2. J Allergy Clin Immunol (2003) 112(6):1066–73. doi:10.1067/mci.2003.101223

74. Grüning G, Warnock M, Wick AE, Venkenkay R, Brombacher F, Remick DM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science (1998) 282(5397):2261–3. doi:10.1126/science.282.5397.2261

75. Hallstrand TS, Henderson WR Jr. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol (2010) 10(1):60–6. doi:10.1097/ACO.0b013e32833489c3

76. Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O’Neill KR, et al. A critical role for eosinophils in allergic airways remodeling. Science (2004) 305(5691):1776–9. doi:10.1126/science.1100283

77. Humbles AA, Lloyd CM, MacMillan SJ, Friend DS, Xanthou G, McKenna EE, et al. The biology of eosinophils and their role in asthma. Am J Respir Crit Care Med (2003) 167(10):1360–8. doi:10.1164/rccm.200209-1030OC

78. Frigas E, Gleich GJ. The eosinophil and the pathophysiology of asthma. Clin Immunol (2005) 114(4):148–52. doi:10.1016/j.clim.2005.02.002

79. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Eur J Pharmacol (2004) 500(1–3):553–61. doi:10.1016/j.ejphar.2004.07.044

80. Torrego A, Hew M, Oates T, Sukkar M, Fan Chung K. Expression and activation of TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasis. Am J Physiol Lung Cell Mol Physiol (2006) 291(6):L1277–85. doi:10.1152/ajplung.00057.2006

81. Ben-Zimra M, Bachelet I, Seaf M, Gleich GJ, Levi-Schaffer F. Eosinophil major basic protein stimulates migration of human lung fibroblasts in vitro. Scand J Immunol (2009) 69(4):381–6. doi:10.1111/j.1365-3083.2009.02233.x

82. Korkmaz AU, Klonine J, Venge P, Eskelinen L, Saarinen S, Moilanen L, et al. Identification of antigen-presenting cells in the lung during chronic airway inflammation. Eur J Immunol (2004) 34(9):2585–93. doi:10.1002/eji.200423605

83. Humbles AA, Lloyd CM, MacMillan SJ, Friend DS, Xanthou G, McKenna EE, et al. A critical role for eosinophils in allergic airways remodeling. J Immunol (2003) 170(9):4774–81. doi:10.4049/jimmunol.170.9.4774

84. Spitz SA, Schwartz A, Weder W, Rabe KF, Ley K. The functional role of the macrophage in chronic airway inflammation. Am J Physiol Lung Cell Mol Physiol (2005) 288(4):L805–12. doi:10.1152/ajplung.00028.2004

85. Vignola AM, Chanez P, Chiappara G, Merendino A, Pace E, Zappalà V, et al. Sputum metalloproteinase-9/MMP-9, activator of metalloproteinase-9, and chronic bronchitis. Am J Respir Crit Care Med (1998) 157(6):1945–50. doi:10.1164/ajrccm.157.6.9803014

86. McMillan SJ, Xanthou G, Lloyd CM. Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-beta antibody: effect on the Smad signaling pathway. J Immunol (2005) 174(9):5774–80. doi:10.4049/jimmunol.174.9.5774

87. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway remodeling in asthma: effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. J Allergy Clin Immunol (2006) 117(5):1036–41. doi:10.1016/j.jaci.2006.05.011

88. Hovding W, Sjølberg KS, Svennevig JL, et al. IL-17 is dispensable for airway vascular remodeling in asthmatic mouse. J Immunol (2015) 195(4):2931–40. doi:10.4049/jimmunol.1402731

89. Payne DN, Rogers AV, Adelroth E, Bandi V, Guntupalli KK, Bush A, et al. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med (1997) 156(2 Pt 1):391–9. doi:10.1164/ajrccm.156.2.9609066

90. McMillan SJ, Xanthou G, Lloyd CM, Ebbesen M, Ring J, Finger DC, et al. Transforming growth factor-beta induces airway smooth muscle hyper trophy. Am J Respir Cell Mol Biol (2006) 34(2):247–54. doi:10.1165/rcmb.2005-0166OC

91. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Eur J Pharmacol (2004) 500(1–3):553–61. doi:10.1016/j.ejphar.2004.07.044

92. Phipps S, Ying S, Wangoo A, Ong YE, Levi-Schaffer F, Kay AB. The relationship between IL-13 and chronic bronchitis. J Allergy Clin Immunol (2010) 126(1):1–8. doi:10.1016/j.jaci.2009.11.022

93. Ben-Zimra M, Bachelet I, Seaf M, Gleich GJ, Levi-Schaffer F. Eosinophil major basic protein activates human cord blood mast cells primed with fibroblast membrane factors by integrin-beta2. J Allergy Clin Immunol (2003) 112(6):1066–73. doi:10.1067/mci.2003.101223

94. Ohno I, Lea RG, Flanders KC, Clark DA, Banwait D, Dolovich J, et al. Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1). J Clin Invest (1992) 90(5):1662–8. doi:10.1172/JCI115764

95. Bilakinde T, Murphy RF, Agrawal DK. The regulatory role of TGF-beta in airway remodeling in asthma. Immunol Cell Biol (2007) 85(5):348–56. doi:10.1038/isci.7100044

96. Goldsmith AM, Bentley JK, Zhou L, Jia Y, Bitar KN, Fingar DC, et al. Transforming growth factor-beta induces airway smooth muscle hypertrophy. Am J Respir Cell Mol Biol (2006) 34(2):247–54. doi:10.1165/rcmb.2005-0166OC

97. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Eur J Pharmacol (2004) 500(1–3):553–61. doi:10.1016/j.ejphar.2004.07.044

98. Torrego A, Hew M, Oates T, Sukkar M, Fan Chung K. Expression and activation of TGF-beta isoforms in acute allergen-induced remodeling in asthma. Thorax (2007) 62(4):307–12. doi:10.1136/thx.2006.063487

99. Frigas E, Gleich GJ. The eosinophil and the pathophysiology of asthma. Clin Immunol (2005) 114(4):148–52. doi:10.1016/j.clim.2005.02.002
chronic allergic airway inflammation. *Eur Rev Med Pharmacol Sci* (2015) 19(12):2261–8.

114. Peterson WR Jr, Chang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. *Am J Respir Crit Care Med* (2006) 173(7):718–28. doi:10.1164/rccm.200501-088OC.

115. Kampf C, Relova AJ, Sandler S, Roomans GM. Effects of TNF-alpha, IFN-gamma and IL- beta on normal human bronchial epithelial cells. *Eur Respir J* (1999) 14(1):84–91. doi:10.1183/09031993.99.14a15.x.

116. Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. *Am J Respir Cell Mol Biol* (2005) 32(4):342–9. doi:10.1165/rcmb.2004-028OOC.

117. Halwani R, Vazquez-Tello A, Suni Y, Pureza MA, Bahammam A, AlJahdali H, et al. Eosinophils induce airway smooth muscle cell proliferation. *J Clin Immunol* (2013) 33(3):595–604. doi:10.1007/s10875-012-9836-3.

118. Fanat AI, Thomson JV, Radford K, Nair P, Sehmi R. Human airway smooth muscle promotes eosinophil differentiation. *Clin Exp Allergy* (2009) 39(7):1009–17. doi:10.1111/j.1365-2222.2009.03246.x.

119. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. *J Allergy Clin Immunol* (2016) 388(10056):2115–27. doi:10.1016/S0140-6736(16)31322-8.

120. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. *Int Immunol* (2013) 25(6):1344–53. doi:10.1093/intimm/dxu039.

121. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet* (2016) 388(10056):2115–27. doi:10.1016/S0140-6736(16)31324-1.

122. Halwani R, Vazquez-Tello A, Suni Y, Pureza MA, Bahammam A, AlJahdali H, et al. Eosinophils induce airway smooth muscle cell proliferation. *J Clin Immunol* (2013) 33(3):595–604. doi:10.1007/s10875-012-9836-3.

123. Kannan T, Ushio H, Koyama H, Okada M, Oikawa M, Yoshihara T, et al. 2.5S nerve growth factor enhances survival, phagocytosis, and superoxide production of murine neutrophils. *Blood* (1991) 77(6):1320–5.

124. Akuthota P, Wang H, Weller PF. Eosinophils as antigen-presenting cells in allergic upper airway disease. *Curr Opin Allergy Clin Immunol* (2010) 10(1):14–9. doi:10.1097/ACOI.0b013e3283346693.

125. Shi HZ, Humbles A, Gerard C, Jin Z, Weller PF. Lymph node trafficking and antigen presentation by endobronchial eosinophils. *J Clin Invest* (2000) 105(7):945–53. doi:10.1172/JCI8945.

126. Cocks BG, de Waal Malefyt R, Galizzi JP, de Vries JE, Aversa G. IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. *Int Immunol* (1999) 5(6):657–63. doi:10.1039/intimm.5.6.657.

127. Gheva RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch recombination. *Nat Rev Immunol* (2003) 3(9):721–32. doi:10.1038/nri1085.

128. Chu VT, Fröhlich A, Steinhauer G, Scheel T, Roch T, Fillatreau S, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. *Nat Immunol* (2011) 12(2):151–9. doi:10.1038/nii.1981.

129. Jourdan M, Cren M, Robert N, Bolloré K, Fest T, Duperray C, et al. IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. *Leukemia* (2014) 28(8):1647–56. doi:10.1038/leu.2014.61.

130. Liu LY, Bates ME, Jarjour NN, Busse WW, Bertsch PJ, Kelly EA. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha. *J Immunol* (2007) 179(7):4840–8. doi:10.4049/jimmunol.179.7.4840.

131. Odemuyiwa SO, Ghahary A, Li Y, Puttagunta L, Lee JE, Musat-Marucu S, et al. Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. *J Immunol* (2004) 173(10):5909–13. doi:10.4049/jimmunol.173.10.5909.

132. Xu H, Zhang GX, Ciric B, Rastomi A. IDO: a double-edged sword for T(H)1/T(H)2 regulation. *Immunol Lett* (2008) 121(1):1–6. doi:10.1016/j.им.2008.08.008.

133. Ravin KA, Loy M. The eosinophil in infection. *Clin Rev Allergy Immunol* (2016) 50(2):214–7. doi:10.1007/s12016-015-8525-4.

134. Akuthota P, Wang H, Weller PF. Eosinophils as antigen-presenting cells in allergic upper airway disease. *Curr Opin Allergy Clin Immunol* (2010) 10(1):14–9. doi:10.1097/ACOI.0b013e3283346693.

135. Luft JR, Yen Y, Liu J, Chen T, He P, Ouyang J, et al. Eosinophil-derived neurotoxin/NRase 2 functions as an effective antiviral agent against respiratory syncytial virus. *J Infect Dis* (1998) 177(6):1458–64. doi:10.1086/515322.

136. Ackerman SJ, Gleich GJ, Loegering DA, Richardson BA, Butterworth AE. Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of *Schistosoma mansoni*. *Am J Trop Med Hyg* (1985) 34(4):735–45. doi:10.4269/ajtmh.1985.34.735.

137. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. *J Leukoc Biol* (2001) 70(5):691–8.

138. Torrent M, Navarro S, Moussaoui M, Nougé MV, Boix E. Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysacharides and peptidoglycans. *Biochemistry* (2008) 47(11):3544–55. doi:10.1021/bi70265b.

139. Ackerman SJ, Gleich GJ, Loegering DA, Richardson BA, Butterworth AE. Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of *Schistosoma mansoni*. *Am J Trop Med Hyg* (1985) 34(4):735–45. doi:10.4269/ajtmh.1985.34.735.

140. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/NRase 2 functions as an effective antiviral agent against respiratory syncytial virus. *J Infect Dis* (1998) 177(6):1458–64. doi:10.1086/515322.

141. Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. *J Biol Chem* (2014) 289(25):17406–15. doi:10.1074/jbc.M113.546218.

142. Yazedbakhsh M, Eckmann CM, Bot AA, Roos D. Bactericidal action of eosinophils from normal human blood. * Infect Immun* (1986) 53(1):192–8.

143. Yousef S, Gold JA, Andina N, Lee JI, Kelly AM, Kozlowski E, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes...
to antibacterial defense. *Nat Med* (2008) 14(9):949–53. doi:10.1038/nm.1855

153. Zeck-Kapp G, Kroegel C, Riede UN, Kapp A. Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations. *Allergy* (1995) 50(1):34–47. doi:10.1111/j.1398-9995.1995.tb02481.x

154. DiScipio RG, Schraufstatter IU. The role of the complement anaphylatoxins in the recruitment of eosinophils. *Int Immunopharmacol* (2007) 7(14):1909–23. doi:10.1016/j.intimp.2007.07.006

155. Shin EH, Osada Y, Sagara H, Takatsu K, Kojima S. Involvement of complement and fibronectin in eosinophil-mediated damage to *Nippostrongylus brasiliensis* larvae. *Parasite Immunol* (2001) 23(1):27–37. doi:10.1046/j.1365-3024.2001.00352.x

156. Giacomin PR, Gordon DL, Botto M, Daha MR, Sanderson SD, Taylor SM, et al. The role of complement in innate, adaptive and eosinophil-dependent immunity to the nematode *Nippostrongylus brasiliensis*. *Mol Immunol* (2008) 45(2):446–55. doi:10.1016/j.molimm.2007.05.029

157. Porter PC, Lim DJ, Maskatia ZK, Mak G, Tsai CL, Citardi MJ, et al. Airway surface mycosis in chronic TH2-associated airway disease. *J Allergy Clin Immunol* (2014) 134(2):325–31. doi:10.1016/j.jaci.2014.04.028

158. Papadopoulos NG, Stanciu LA, Papi A, Holgate ST, Johnston SL. A defective type 1 response to rhinovirus in atopic asthma. *Thorax* (2002) 57(4):328–32. doi:10.1136/thorax.57.4.328

159. Wark PA, Johnston SL, Bucchiari F, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. *J Exp Med* (2005) 201(6):937–47. doi:10.1084/jem.20041901

160. Mathur SK, Fichtinger PS, Kelly JT, Lee WM, Gern JE, Jarjour NN. Interaction between allergy and innate immunity: model for eosinophil regulation of epithelial cell interferon expression. *Ann Allergy Asthma Immunol* (2013) 111(1):25–31. doi:10.1016/j.anai.2013.05.010

161. Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. *Am J Respir Crit Care Med* (2011) 184(8):957–63. doi:10.1164/rccm.201104-0655OC

162. Hilty M, Burke C, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. *PLoS One* (2010) 5(1):e8578. doi:10.1371/journal.pone.0008578

163. Sverrild A, Kiilerich P, Pedersen R, Pedsbjerg C, Bergqvist A, et al. Eosinophilic airway inflammation in asthmatic patients is associated with an altered airway microbiome. *J Allergy Clin Immunol* (2016). doi:10.1016/j.jaci.2016.10.046

Conflict of Interest Statement: CM has attended an international conference with Boehringer Ingelheim. AMG has attended advisory boards for Glaxo SmithKline, Novartis, Astra Zeneca, Boehringer Ingelheim and Teva. He has received speaker fees from Novartis, Astra Zeneca, Vectura, Boehringer Ingelheim and Teva. He has participated in research for which his institution has been renumerated with Hoffman La Roche, Glaxo SmithKline and Boehringer Ingelheim. He has attended international conferences with Napp and Astra Zeneca and has consultancy agreements with Astra Zeneca and Vectura.

Copyright © 2017 McBrien and Menzies-Gow. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.